The high incidence of HD in western countries, large R&D investments for the development of innovative medicines, and research collaborations are all contributing to the growth of Huntingtin's disease market globally. Huntington's disease is a rare genetic neurological condition that runs in families. The condition affects people in their adult age, making it difficult for them to work, take care of their families, and do daily tasks. However, the currently authorized drugs only provide palliative care and treat the condition's symptoms. Drugs may diminish a patient's symptom severity, but they are commonly associated with side effects that can significantly lower a patient's quality of life, including somnolence, gait issues, dysphagia, and apathy. Given the absence of a cure for the condition, it is critical to evaluate how these patients' health-related quality of life (HRQOL) is impacted. Patients with early to mid-stage HD require integrated, multidisciplinary healthcare interventions, including as counselling and cognitive function evaluations.

The global COVID-19 led to a downturn in the market for Huntington's disease treatments. During the pandemic, internet pharmacies marketed off-label drugs to treat HD symptoms, including antidepressants, antipsychotics, and anticonvulsants. The government shutdown forced the suspension of clinical trials during the COVID-19 epidemic.

The Global Huntington’s Disease Market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as;  Annexon Biosciences, Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, H. Lundbeck A/S, Hetero, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc., SOM Biotech, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UniQure, Vaccinex, Inc.

SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2032. This report provides data for growth estimates and forecasts for product type segment –By Treatment (Symptomatic treatment, Disease-modifying therapies).

This report also provides the data for key regional segments of North America, Europe, Asia-Pacific and Rest of the World. 

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.